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Introduction {#jah31924-sec-0004}
============

Coronary artery disease (CAD) is the leading cause of death, morbidity, and disability in Western countries.[1](#jah31924-bib-0001){ref-type="ref"} Among CAD patients, acute coronary syndrome (ACS) represents a serious concern because of the major adverse cardiac events (MACE) during follow‐up.[2](#jah31924-bib-0002){ref-type="ref"}

ACS may develop from the erosion or rupture of obstructive (due to thrombus formation) or nonobstructive coronary atherosclerotic plaques.[3](#jah31924-bib-0003){ref-type="ref"}, [4](#jah31924-bib-0004){ref-type="ref"} The latter condition, commonly defined as nonobstructive CAD (NObCAD), is less common than obstructive CAD (ObCAD), with a prevalence ranging from 5% to 25%,[5](#jah31924-bib-0005){ref-type="ref"}, [6](#jah31924-bib-0006){ref-type="ref"} and it has been associated with lower rates of clinical outcomes in several studies.[7](#jah31924-bib-0007){ref-type="ref"}, [8](#jah31924-bib-0008){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}

A recent systematic review compared the death rates of patients with myocardial infarction and nonobstructive versus obstructive coronary arteries.[6](#jah31924-bib-0006){ref-type="ref"} However, no meta‐analyses directly compared the rates of other outcomes including re‐infarction, cardiac death, and MACE in NObCAD versus ObCAD ACS patients.

We carried out a meta‐analysis to compare the likelihood of several clinical outcomes in NObCAD and ObCAD ACS patients, to estimate the rates of events, and to investigate other hypotheses including the potential differences in the prognosis of NObCAD subjects with zero or mild occlusion (0% versus 1--50% stenosis), and the differences in baseline presentation between NObCAD and ObCAD subjects.

Methods {#jah31924-sec-0005}
=======

Search, Study Inclusion Criteria, and Quality Assessment {#jah31924-sec-0006}
--------------------------------------------------------

Study inclusion criteria were as follows: (1) inclusion of patients with obstructive or nonobstructive coronary lesion ACS at baseline; (2) prospective or retrospective assessment of ≥1 of the following outcomes: all‐cause mortality, myocardial infarction, all‐cause mortality plus myocardial infarction, cardiac death, and MACE. The search was initially made online in MedLine, Scopus, EMBASE, and the Cochrane Controlled Clinical Trial Register (up to June 2015, with no language restriction). The bibliographies of all relevant articles including reviews were reviewed. When it was not possible to extract any safety or efficacy outcome from a potentially eligible study, attempts to contact the corresponding author were made. The search string was adjusted for each database while maintaining a common overall architecture. We used various combinations of the following terms related to 2 main domains: "death" OR "all‐cause death" OR "all‐cause mortality" OR "mortality" OR "cardiac death" OR "death for cardiovascular disease" OR "myocardial infarction" OR "re‐infarction" OR "MACE" OR "major adverse cardiovascular events" OR "coronary heart disease" (title/abstract) AND "coronary heart disease" OR "heart disease" OR "cardiovascular disease" OR "acute myocardial infarction" OR "angina\*" OR "acute coronary syndrome" OR "unstable angina" OR "non‐ST segment elevation myocardial infarction (NSTE‐ACS)" OR "ST‐elevation myocardial infarction (STE‐ACS)" OR "coronary angiograms" OR "normal coronary angiograms," OR "near‐normal coronary angiograms" OR "non‐obstructive coronary atherosclerosis" and "obstructive coronary atherosclerosis" OR "insignificant coronary artery disease" OR "significant coronary artery disease" OR "mild coronary artery disease".

We excluded the studies that reported data only on particular subtypes of subjects, eg, ACS due to spontaneous coronary dissection, takotsubo cardiomyopathy, or myocarditis, as well as studies in which coronary angiography in the acute phase of ACS was not performed. When both ACS and stable CAD patients were included in a study, we included the study only if data on ACS subjects could be extracted separately.

Because all the retrieved studies were observational or observational subgroup analyses of randomized trials, we assessed the aspects of the reported methodological quality using an adapted version of the Newcastle Ottawa Quality Assessment Scale, evaluating the comparability across groups at baseline for confounding factors (and examining whether analyses were adjusted adequately for confounders), the appropriateness of outcome assessment, length of follow‐up, and missing data handling and reporting.[11](#jah31924-bib-0011){ref-type="ref"}

Data Extraction {#jah31924-sec-0007}
---------------

Using a standardized data extraction form, 2 independent investigators (C.P. and G.M.C.) extracted and tabulated all data. These investigations were not blinded to authors or to institutions. Discrepancies were resolved through revision of the original articles and group discussions. The extracted information included the following: editorial information (lead author, publication year, study size, study design, duration of follow‐up, type and source of financial support, and publication status), clinical presentation of ACS (ST‐elevation acute myocardial infarction, non‐ST‐elevation acute myocardial infarction, and unstable angina), study population information (number of patients for each study, percentage of male population, age, percentage of patients presenting with obstructive and nonobstructive coronary artery disease), coronary risk factors such as smoking, hypertension, dyslipidemia, diabetes mellitus, and findings of coronary angiograms. If the results were presented for more than 1 time‐point, the last available results were extracted.

Outcomes and Data Analysis {#jah31924-sec-0008}
--------------------------

NObCAD was defined as no epicardial vessel with a stenosis ≥50% by quantitative coronary angiography. Nonobstructive lesions were additionally grouped as normal coronary vessels (0% lumen stenosis in all vessels) and mild coronary stenosis (1--49% lumen stenosis in at least 1 vessel).

The main outcome was all‐cause mortality during follow‐up; secondary outcomes were myocardial infarction, all‐cause mortality plus myocardial infarction, cardiac death and MACE, as defined by the authors. The definitions of cardiovascular disease for each included study[7](#jah31924-bib-0007){ref-type="ref"}, [8](#jah31924-bib-0008){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [12](#jah31924-bib-0012){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [16](#jah31924-bib-0016){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [21](#jah31924-bib-0021){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [23](#jah31924-bib-0023){ref-type="ref"}, [24](#jah31924-bib-0024){ref-type="ref"}, [25](#jah31924-bib-0025){ref-type="ref"}, [26](#jah31924-bib-0026){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [29](#jah31924-bib-0029){ref-type="ref"}, [30](#jah31924-bib-0030){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [33](#jah31924-bib-0033){ref-type="ref"}, [34](#jah31924-bib-0034){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [41](#jah31924-bib-0041){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"} are shown in Table [1](#jah31924-tbl-0001){ref-type="table-wrap"}, together with study characteristics. We extracted both adjusted or propensity score matched estimations and raw data to build 2×2 tables, at any time‐point. However, adjusted or propensity score matched estimates were available from 3 studies only,[7](#jah31924-bib-0007){ref-type="ref"}, [8](#jah31924-bib-0008){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"} and we thus performed all analyses using raw data.

###### 

Characteristics of the Included Studies

  Study                                                                                           Year   Design           N        Non Obstr.   Obstr.   Follow‐up       Extracted Outcomes                                                                                       Study Years   ACS Type                CAD Stratification     ACS Definition/Cardiac Enzyme   Outcome Ascertainment
  ----------------------------------------------------------------------------------------------- ------ ---------------- -------- ------------ -------- --------------- -------------------------------------------------------------------------------------------------------- ------------- ----------------------- ---------------------- ------------------------------- -----------------------------------------------
  Studies included in all meta‐analyses                                                                                                                                                                                                                                                                                                                                        
  Raymond[37](#jah31924-bib-0037){ref-type="ref"}                                                 1988   Observ.          148      74           74       126 months      Death, Cardiac death[a](#jah31924-note-0003){ref-type="fn"}, MI[a](#jah31924-note-0003){ref-type="fn"}   1968--1985    STE‐ACS, NSTE‐ACS       \>50%; ≤50%            Study protocol (Protocol)       Visit
  Roe[39](#jah31924-bib-0039){ref-type="ref"}                                                     2000   RCT              5767     696          5071     1, 6 months     Death, MI                                                                                                1995--1997    NSTE‐ACS, UA            \>50%; 0% to 50%; 0%   Protocol, CK                    Events reporting records
  Da Costa[18](#jah31924-bib-0018){ref-type="ref"}                                                2001   Observ.          176      88           88       34 months       MACE, Cardiac death, MI                                                                                  1994--1999    STE‐ACS, NSTE‐ACS       \>50%; ≤50%            Protocol                        Phone contacts, visit
  Dokainish[7](#jah31924-bib-0007){ref-type="ref"}                                                2005   RCT (sub‐set)    895      107          788      6 months        Death, MI, ACS                                                                                           1997--1999    STE‐ACS NSTE‐ACS, UA    \>50%; ≤50%            Protocol, Troponin              RCT, events reporting records
  Larsen[28](#jah31924-bib-0028){ref-type="ref"}                                                  2005   Observ.          9797     726          9071     12 months       Death                                                                                                    1995--2000    STE‐ACS, NSTE‐ACS       \>50%; 0% to 50%; 0%   ICD codes                       ICD codes
  Pinheiro[34](#jah31924-bib-0034){ref-type="ref"}                                                2005   Observ.          1351     220          1131     In hospital     Death                                                                                                    1996--2002    STE‐ACS, NSTE‐ACS       ≥50%; \<50%            Protocol, CK                    Visit
  Patel[10](#jah31924-bib-0010){ref-type="ref"}                                                   2006   Observ.          38 301   3306         34 995   In hospital     Death, MI                                                                                                2001--2006    NSTE‐ACS                \>50%; ≤50%            Protocol, Troponin, CK          Visit
  Larson[29](#jah31924-bib-0029){ref-type="ref"}                                                  2007   Observ.          1325     187          1138     12 months       Death                                                                                                    2003--2006    STE‐ACS                 \>50%; ≤50%            Protocol, Troponin              Events reporting records
  Terefe[43](#jah31924-bib-0043){ref-type="ref"}                                                  2007   Observ.          112      56           56       39 months       Cardiac death, MI                                                                                        2000--2006    STE‐ACS, NSTE‐ACS,      \>50%; ≤50%            Protocol, Troponin, CK          Not reported
  Dey[19](#jah31924-bib-0019){ref-type="ref"}                                                     2009   Observ.          20 692   1560         19 132   6 months        Death, MI                                                                                                1999--2006    STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, Troponin, CK          Events reporting records
  Dwyer[20](#jah31924-bib-0020){ref-type="ref"}                                                   2008   RCT              180      29           151      12 months       Death+MI                                                                                                 2003--2004    UA, MI                  \>50%; ≤50%            ICD codes                       Medical Records, visit
  Von Korn[44](#jah31924-bib-0044){ref-type="ref"}                                                2008   Observ.          636      127          509      12 months       Death, Cardiac death, MI                                                                                 2002--2005    STE‐ACS, NSTE‐ACS       \>50%; ≤50%            Protocol, Troponin, CK          Phone contacts, visit
  Cortell[17](#jah31924-bib-0017){ref-type="ref"}                                                 2009   Observ.          504      64           440      36 months       Death, MI                                                                                                2001--2008    NSTE‐ACS                \>50%; ≤50%            Protocol, Troponin              Not reported
  Kang[27](#jah31924-bib-0027){ref-type="ref"}                                                    2011   Observ.          3056     126          2930     6, 12 months    MACE, Death, Cardiac death, MI                                                                           2005--2006    STE‐ACS, NSTE‐ACS       \>50%; ≤50%            Protocol, Troponin, CK          Phone contact, visit
  Ramanath[36](#jah31924-bib-0036){ref-type="ref"}                                                2010   Observ.          2264     123          2141     6 months        MACE, Death, MI                                                                                          1999--2004    STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, Troponin, CK          Phone contact
  Hamdan[22](#jah31924-bib-0022){ref-type="ref"}                                                  2012   Observ.          124      11           113      In hospital     Death                                                                                                    2008--2009    STE‐ACS, NSTE‐ACS       ≥50%; \<50%            Protocol, Troponin              Visit
  Rhew[38](#jah31924-bib-0038){ref-type="ref"}                                                    2012   Observ.          1220     100          1120     1, 12 months    MACE, Death, Cardiac death, MI                                                                           2006--2008    STE‐ACS, NSTE‐ACS,      \>50%; ≤50%            Protocol, Troponin, CK          Phone contacts, Hospital database
  Sun[42](#jah31924-bib-0042){ref-type="ref"}                                                     2012   Observ.          695      49           646      36 months       MACE, Death, Cardiac death, MI                                                                           2007--2008    STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, Troponin, CK          Medical records, GPs, death certificates
  Rossini[40](#jah31924-bib-0040){ref-type="ref"}                                                 2013   Observ.          1206     888          318      26 months       MACE, Death, MI                                                                                          2009          STE‐ACS, NSTE‐ACS, UA   \>50%; 0% to 50%; 0%   Protocol, Troponin              Events reporting records
  Manfrini[30](#jah31924-bib-0030){ref-type="ref"}                                                2014   Observ.          1602     350          1252     6 months        Cardiac death                                                                                            2003          STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, Troponin              Events reporting records
  Minha[31](#jah31924-bib-0031){ref-type="ref"}                                                   2014   Observ.          3686     163          3523     1, 12 months    MACE (30 days), Death                                                                                    2004--2010    STE‐ACS, NSTE‐ACS, UA   \>50%; 0% to 50%; 0%   Protocol, Troponin, CK          Phone contacts, visit
  Planer[35](#jah31924-bib-0035){ref-type="ref"}                                                  2014   RCT (subset)     2442     197          2245     1, 12 months    Death, Cardiac death, MI                                                                                 2003--2005    NSTE‐ACS, UA            \>50%; ≤50%            Protocol, Troponin              Events reporting records
  Studies included only in the meta‐analyses of event rates by single group                                                                                                                                                                                                                                                                                                    
  Harris[9](#jah31924-bib-0009){ref-type="ref"}                                                   1980   Observ.          1183     0            1183     6, 12 months    Death, Cardiac death, MI                                                                                 1973--1978    STE‐ACS                 \>50%                  Protocol                        Phone contacts, visit
  Hung[25](#jah31924-bib-0025){ref-type="ref"}                                                    2003   Observ.          19       19           0        24 months       Death, Cardiac death                                                                                     1998--2000    STE‐ACS, NSTE‐ACS       \>50%                  Protocol, CK                    Phone contacts, visit
  Golzio[8](#jah31924-bib-0008){ref-type="ref"}                                                   2004   Observ.          53       53           0        125 months      Death, Cardiac death                                                                                     1985--1990    STE‐ACS, NSTE‐ACS       ≤50%; 0%               Protocol, CK                    Phone contacts, visit
  Bugiardini[14](#jah31924-bib-0014){ref-type="ref"}                                              2006   3 RCT (subset)   701      701          0        12 months       MACE, Death, MI                                                                                          1996--2001    NSTE‐ACS, UA            \<50%; 0%              Protocol, CK                    Medical records, visit
  Shishehbor[41](#jah31924-bib-0041){ref-type="ref"}                                              2007   Observ.          1240     0            1240     28 months       Death, MI                                                                                                1995--2005    NSTE‐ACS, UA            ≥50%                   Protocol, Troponin, CK          Medical records, phone contacts
  Chan[15](#jah31924-bib-0015){ref-type="ref"}                                                    2008   Observ.          8225     0            8225     6, 12 months    Death, MI (6 months)                                                                                     2001--2003    NSTE‐ACS, UA            \>50%                  Protocol, Troponin, CK          Medical records, phone contacts, visit
  Hansen[23](#jah31924-bib-0023){ref-type="ref"}                                                  2012   Observ.          1595     1595         0        36 months       Death, MI                                                                                                2005--2007    STE‐ACS, NSTE‐ACS       ≤50%                   Protocol, CK                    ICD codes
  Abid[12](#jah31924-bib-0012){ref-type="ref"}                                                    2012   Observ.          21       21           0        24 months       Death, MI                                                                                                2006--2011    STE‐ACS                 \>50%                  Protocol, CK                    Medical records, phone contacts
  Aldous[13](#jah31924-bib-0013){ref-type="ref"}                                                  2015   Observ.          351      351          0        24 months       Death, Cardiac death, MI                                                                                 2007--2011    STE‐ACS, NSTE‐ACS       \<50%                  Protocol, Troponin              Medical records
  Johnston[26](#jah31924-bib-0026){ref-type="ref"}                                                2015   Observ.          10 588   10 588       0        31 months       Death, MI                                                                                                2005--2010    STE‐ACS, NSTE‐ACS       \<50%                  Protocol, Troponin              National registry, Medical records
  Ohlow[32](#jah31924-bib-0032){ref-type="ref"}                                                   2015   Observ.          393      204          189      27, 17 months   Death, Cardiac death, MI                                                                                 2002--2011    STE‐ACS, NSTE‐ACS       \>50%; 0% to 50%; 0%   Protocol, Troponin              Medical records, GPs, phone contacts, visit
  Studies included in meta‐analyses of single groups on the baseline proportion of STE‐ACS only                                                                                                                                                                                                                                                                                
  Hochman[24](#jah31924-bib-0024){ref-type="ref"}                                                 1999   RCT              6406     737          5669     1 month         Baseline % of STE‐ACS                                                                                    1994--1996    STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, CK                    Events reporting records
  Germing[21](#jah31924-bib-0021){ref-type="ref"}                                                 2005   Observ.          897      76           821      26 months       Baseline % of STE‐ACS                                                                                    1996--2000    STE‐ACS, UA             \>50%; ≤50%            Protocol, Troponin, CK          Questionnaire, Phone contact, Medical records
  Ong[33](#jah31924-bib-0033){ref-type="ref"}                                                     2008   Observ.          488      138          350      0 months        Baseline % of STE‐ACS                                                                                    2006          STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, Troponin, CK          ---
  Chokshi[16](#jah31924-bib-0016){ref-type="ref"}                                                 2010   Observ.          518      106          412      0 months        Baseline % of STE‐ACS                                                                                    2006          STE‐ACS, NSTE‐ACS, UA   \>50%; ≤50%            Protocol, not reported          ---

ACS indicates acute coronary syndrome; CAD, coronary artery disease; CK, creatine kinase; GPs, general practitioners; ICD, International Classification of Diseases; MACE, major adverse cardiac events; MI, myocardial infarction; N, Number of subjects for whom data were extracted and used in the analyses; NSTE, non‐ST segment elevation; Observ., observational; Obstr., obstructive; RCT, randomized controlled trial; UA, unstable angina.

Only for the meta‐analyses of event rates by group: no data were provided on the nonobstructive coronary artery disease group.
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The primary, prespecified hypothesis of the study was that clinical outcomes were significantly less frequent in NObCAD than ObCAD patients. This hypothesis was evaluated through random‐effect head‐to‐head meta‐analyses, which included only the studies reporting data on both ObCAD and NObCAD subjects.[45](#jah31924-bib-0045){ref-type="ref"} All analyses were stratified by follow‐up duration (1--6 months, ≥12 months). The results were expressed with risk ratio (RR) and 95% CI, and the statistical heterogeneity was quantified using the I^2^ metric.[46](#jah31924-bib-0046){ref-type="ref"}

In order to provide some estimates of the incidence rates for each selected outcome, we also performed meta‐analyses of event rates (sometimes defined as "proportion meta‐analysis") combining the data of NObCAD and ObCAD patients separately.[47](#jah31924-bib-0047){ref-type="ref"} Thus, in such analyses we could also include the studies reporting data on NObCAD subjects only (or data on ObCAD patients only), and study crude rates were divided by the number of months of follow‐up to estimate the monthly and yearly rates for each outcome.

Two secondary hypotheses were also investigated: (1) among NObCAD subjects, some clinical outcomes may be less frequent in patients with normal artery CAD (0% stenosis) versus mildly obstructive CAD (1--50% stenosis); (2) NObCAD patients, as compared to ObCAD subjects, may have less cardiovascular risk factors at baseline (including higher age, male sex, diabetes mellitus, hypertension, dyslipidemia, current cigarette smoking), and they may less frequently present with STE‐ACS at hospital discharge and be treated with cardiovascular drugs such as angiotensin‐converting enzyme inhibitors, β‐blockers, statins, aspirin, or P2Y12 inhibitors. As for the primary hypothesis, we used random‐effect meta‐analyses comparing the 2 groups directly, and we estimated the crude outcome rates (or baseline proportions) in both groups through meta‐analyses of the event rates. A random‐effect generic inverse variance approach was used to estimate the mean age at baseline within single groups.

Potential publication bias was assessed using funnel plots (displaying RRs from individual studies versus their precision \[1/SE\]), and formally tested through the Egger regression asymmetry test.

We used StatsDirect 2.7.8 (StatsDirect Ltd, Altrincham, UK, 2010) and RevMan 5.3 (The Cochrane Collaboration, 2014), to perform, respectively, the meta‐analyses of the event rates and the meta‐analyses comparing directly NObCAD versus ObCAD patients.

Results {#jah31924-sec-0009}
=======

Search Results and Overall Study Characteristics {#jah31924-sec-0010}
------------------------------------------------

Of the 984 papers initially retrieved ([Figure](#jah31924-fig-0001){ref-type="fig"}), we identified 33 studies (including a total of 120 548 participants) that evaluated the selected cardiovascular outcomes in NObCAD and/or ObCAD patients.[1](#jah31924-note-1002){ref-type="fn"} Of those, 11 studies (24 369 participants) did not compare directly NObCAD versus ObCAD patients, and thus could be included only in the meta‐analyses estimating the rates of each selected outcome by single group.[2](#jah31924-note-1003){ref-type="fn"} Four other studies (8309 participants) were included only in the meta‐analyses evaluating the baseline proportion of STE‐ACS patients by single group.[16](#jah31924-bib-0016){ref-type="ref"}, [21](#jah31924-bib-0021){ref-type="ref"}, [24](#jah31924-bib-0024){ref-type="ref"}, [33](#jah31924-bib-0033){ref-type="ref"}

![Flowchart of the studies. NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease.](JAH3-5-e004185-g001){#jah31924-fig-0001}

As reported in Table [1](#jah31924-tbl-0001){ref-type="table-wrap"}, 7 of the 33 included studies were carried out in the United States, 10 in Europe, 6 studies were international, and the remaining 10 took place in other countries. Three studies were re‐analyses of randomized controlled trials,[7](#jah31924-bib-0007){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"} 3 studies were randomized controlled trials,[20](#jah31924-bib-0020){ref-type="ref"}, [24](#jah31924-bib-0024){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"} and all the others had an observational design. Seventeen studies had a sample size \>1000; 12 were published after 2010; 25 had a follow‐up ≥12 months. Eight studies further categorized NObCAD patients in mildly versus zero obstructive CAD, and could thus be included into a dedicated meta‐analysis. In 15 studies the outcomes were ascertained through medical visits. The included studies differed widely in the proportion of NObCAD patients and in several baseline patient\'s characteristics, including the mean age, the percentage of males, diabetics, hypertensive, dyslipidemic, smokers, and subjects with STE‐ACS, unstable angina, and non‐ST elevation myocardial infarction--ACS (Table S1).

Also, because of the large time span of the studies included, and sometimes to their long follow‐up, the definition of ACS has been quite heterogeneous both within and across the studies. Before the Myocardial Universal Definition of 2007, ACS was defined on the basis of symptoms, ECG abnormalities, and cardiac enzymes (mainly creatine kinase MB fraction).[48](#jah31924-bib-0048){ref-type="ref"} After 2007, the measurement of cardiac troponin T or I has been preferred over the measurement of creatine kinase MB fraction or other biomarkers for ACS diagnosis. Of the 33 included studies, 12 were published before 2007, and only 1 of these dosed serum troponin and gave results differentiating unstable angina from non‐ST‐segment elevation myocardial infarction.[7](#jah31924-bib-0007){ref-type="ref"} After 2007, only 10 studies[3](#jah31924-note-1004){ref-type="fn"} considered patients with unstable angina, and none reported outcomes stratified by type of ACS.

Methodological Quality {#jah31924-sec-0011}
----------------------

The methodological characteristics of the included studies, as measured by the Newcastle Ottawa Quality Assessment Scale,[11](#jah31924-bib-0011){ref-type="ref"} are summarized in Table S2. Almost all studies adequately selected the cohort of patients and ascertained the exposure (selection category items); 22 of the 33 studies adequately addressed at least 2 of the 3 items referred to outcome assessment and follow‐up (length and missing data). Among the 22 studies included in head‐to‐head meta‐analyses, the comparability of NObCAD versus ObCAD subjects was not addressed in 14 studies, and only 8 studies reported some form of adjustment for potential confounders.

Differences in the Baseline Characteristics of NObCAD Versus ObCAD Patients {#jah31924-sec-0012}
---------------------------------------------------------------------------

As compared with ObCAD subjects, NObCAD patients were significantly younger (−6.2 years on average), less likely to be male (RR=0.77), diabetic (RR=0.57), hypertensive (RR=0.87), dyslipidemic (RR=0.75), and to be treated with angiotensin‐converting enzyme inhibitors (RR=0.86; 47.0% versus 53.7% among ObCAD patients), β‐blockers (RR=0.83; 70.0% versus 79.4%), statins (RR=0.82; 52.1% versus 64.2%), and P2Y12 inhibitors (RR=0.46; 29.2% versus 63.7%) (all *P*\<0.01; Table [2](#jah31924-tbl-0002){ref-type="table-wrap"}, Figures S1 through S11). The rate of aspirin treatment was not significantly different (RR=0.94; 81.7% versus 86.8% among ObCAD).

###### 

Meta‐Analyses Comparing the Baseline Characteristics of NObCAD Versus ObCAD Patients

  Baseline Characteristics   No. Studies (Total Sample)   n/N                          Risk Ratio (95% CI)   *P* Value   I^2^, %
  -------------------------- ---------------------------- ---------------------------- --------------------- ----------- ---------
  Male sex                   22 (81 586)                  3686/7420 vs 50 870/74 166   0.77 (0.72--0.84)     \<0.001     88
  Diabetes mellitus          22 (81 586)                  1247/7420 vs 22 166/74 166   0.57 (0.47--0.78)     \<0.001     86
  Hypertension               22 (81 586)                  4099/7420 vs 45 511/74 166   0.87 (0.81--0.93)     \<0.001     82
  Dyslipidemia               22 (81 586)                  2680/7420 vs 31 035/74 166   0.75 (0.65--0.87)     \<0.001     93
  Current smoking            22 (81 586)                  2422/7420 vs 29 282/74 166   0.94 (0.85--1.03)     0.2         81
  STE‐ACS                    11 (21 856)                  365/2229 vs 14 382/19 627    0.20 (0.13--0.29)     \<0.001     93
  ACE‐inhibitors use         8 (76 380)                   3052/6499 vs 37 554/69 881   0.86 (0.80--0.92)     \<0.001     78
  β‐Blockers use             8 (76 380)                   4419/6499 vs 55 486/69 881   0.83 (0.75--0.93)     0.001       96
  Statins use                8 (76 380)                   3389/6499 vs 44 892/69 881   0.82 (0.70--0.95)     0.01        98
  Aspirin use                8 (76 380)                   5311/6499 vs 60 675/69 881   0.94 (0.88--1.01)     0.08        96
  P2Y12 inhibitors use       6 (48 023)                   1197/4118 vs 27 951/43 905   0.46 (0.39--0.55)     \<0.001     85

  Baseline Characteristics     No. Studies (Total Sample)   N/N           Mean Difference (95% CI)   *P* Value   I^2^, %
  ---------------------------- ---------------------------- ------------- -------------------------- ----------- ---------
  Mean age                     21 (81 438)                  7346/74 092   −6.16 (−7.85; −4.47)       \<0.001     94
  Mean LVEF                    6 (11 245)                   553/10 692    2.44 (0.50; 4.39)          0.01        65
  Mean Troponin level, ng/mL   4 (9822)                     295/9527      −27.2 (−10.5; −43.8)       \<0.001     97

ACE indicates angiotensin‐converting enzyme; LVEF, left ventricular ejection fraction; n, number of nonobstructive coronary artery disease subjects; N, number of obstructive coronary artery disease participants; NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease; STE‐ACS, ST‐elevation myocardial infarction.

John Wiley & Sons, Ltd

Although a few studies reported baseline levels of troponin and left ventricular ejection fraction in both groups, the 2 prognostic parameters were significantly better in NObCAD versus ObCAD subjects (+2.44% and −27.2 ng/mL, respectively; both *P*\<0.05) (Figures S12 and S13).

Overall, the likelihood of being diagnosed with STE‐ACS (rather than non‐ST segment elevation--ACS) at baseline was drastically lower among NObCAD versus ObCAD patients (RR=0.20; 95% CI: 0.13--0.29; Table [2](#jah31924-tbl-0002){ref-type="table-wrap"}, Figure S14).

The estimated rates of the above characteristics at baseline were computed using meta‐analyses by single group and are reported in Table S3 and Figures S15 through S38. Overall, the results were in line with the meta‐analyses comparing the 2 groups directly: among NObCAD and ObCAD patients, respectively, the mean ages were 56.9 and 63.2 years, and the proportions of STE‐ACS were 14.7% and 73.8%.

Crude Rates of Cardiovascular Outcomes in NObCAD and ObCAD Patients {#jah31924-sec-0013}
-------------------------------------------------------------------

Overall, 33 studies were included in at least 1 meta‐analysis to estimate the rates of cardiovascular outcomes in NObCAD and ObCAD patients (Table [3](#jah31924-tbl-0003){ref-type="table-wrap"}). In NObCAD patients, the combined yearly rates of death, myocardial infarction, death plus myocardial infarction, cardiac death, and MACE were 2.4%, 1.4%, 4.0%, 1.2%, and 9.2%, respectively (Table [3](#jah31924-tbl-0003){ref-type="table-wrap"}, Figures S39 through S43). The same rates in ObCAD patients were 10.1%, 5.9%, 12.8%, 6.0%, and 16.8% (Table [3](#jah31924-tbl-0003){ref-type="table-wrap"}, Figures S44 through S48).

###### 

Meta‐Analyses of the Event Rates by Single Group of CAD Patients

  Outcomes                                 ObCAD (\>50% Stenosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NObCAD (0--50% Stenosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Zero CAD (0% Stenosis)                                                                                                                                                                                                                                                                                                                                     Mild CAD (1--50% Stenosis)
  ---------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  MACE                                     References [18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       References [14](#jah31924-bib-0014){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       References [14](#jah31924-bib-0014){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}                                                                                                                                                                                                                    References [14](#jah31924-bib-0014){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}
  No. studies (n/N; total person‐months)   7 (2039/11 322; 152 890)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              8 (184/1668; 26 842)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                                                                                                                                                                                                                        ---
  Estimated pooled rate (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Per month                                1.40% (0.61%; 2.50%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.77% (0.43%; 1.21%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                                                                                                                                                                                                                        ---
  Per year                                 16.8% (7.32%; 30.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  9.24% (5.16%; 14.5%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                                                                                                                                                                                                                        ---
  All deaths                               References [7](#jah31924-bib-0007){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [29](#jah31924-bib-0029){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [34](#jah31924-bib-0034){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [41](#jah31924-bib-0041){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}   References [1](#jah31924-bib-0001){ref-type="ref"}, [2](#jah31924-bib-0002){ref-type="ref"}, [4](#jah31924-bib-0004){ref-type="ref"}, [5](#jah31924-bib-0005){ref-type="ref"}, [6](#jah31924-bib-0006){ref-type="ref"}, [7](#jah31924-bib-0007){ref-type="ref"}, [8](#jah31924-bib-0008){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [11](#jah31924-bib-0011){ref-type="ref"}, [12](#jah31924-bib-0012){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [16](#jah31924-bib-0016){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [24](#jah31924-bib-0024){ref-type="ref"}, [26](#jah31924-bib-0026){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}   References [8](#jah31924-bib-0008){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}   References [8](#jah31924-bib-0008){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}
  No. studies (n/N; total person‐months)   22 (3996/95 895; 657 036)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             26 (1007/21 652; 472 754)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       8 (31/1498; 23 824)                                                                                                                                                                                                                                                                                                                                        8 (49/1714; 28 257)
  Estimated pooled rate (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Per month                                0.84% (0.53%; 1.23%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.20% (0.14%; 0.27%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            0.11% (0.05%; 0.19%)                                                                                                                                                                                                                                                                                                                                       0.09% (0.04%; 0.15%)
  Per year                                 10.1% (6.36%; 14.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2.38% (1.69%; 3.18%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1.28% (0.59%; 2.24%)                                                                                                                                                                                                                                                                                                                                       1.05% (0.48%; 1.85%)
  Cardiac death                            References [9](#jah31924-bib-0009){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [30](#jah31924-bib-0030){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          References [1](#jah31924-bib-0001){ref-type="ref"}, [3](#jah31924-bib-0003){ref-type="ref"}, [11](#jah31924-bib-0011){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [16](#jah31924-bib-0016){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [21](#jah31924-bib-0021){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [24](#jah31924-bib-0024){ref-type="ref"}, [25](#jah31924-bib-0025){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                 References [8](#jah31924-bib-0008){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}                                                                                                                                                                                                                     References [8](#jah31924-bib-0008){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}
  No. studies (n/N; total person‐months)   10 (713/10 218; 135 001)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              13 (54/1794; 43 937)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                                                                                                                                                                                                                        ---
  Estimated pooled rate (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Per month                                0.50% (0.15%; 1.09%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.10% (0.03%; 0.20%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                                                                                                                                                                                                                        ---
  Per year                                 6.00% (1.79%; 13.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.22% (0.42%; 2.45%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ---                                                                                                                                                                                                                                                                                                                                                        ---
  MI                                       References [7](#jah31924-bib-0007){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [41](#jah31924-bib-0041){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                 References [1](#jah31924-bib-0001){ref-type="ref"}, [2](#jah31924-bib-0002){ref-type="ref"}, [3](#jah31924-bib-0003){ref-type="ref"}, [4](#jah31924-bib-0004){ref-type="ref"}, [7](#jah31924-bib-0007){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [11](#jah31924-bib-0011){ref-type="ref"}, [12](#jah31924-bib-0012){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [16](#jah31924-bib-0016){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [21](#jah31924-bib-0021){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [23](#jah31924-bib-0023){ref-type="ref"}, [26](#jah31924-bib-0026){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}                                                                                                                                                                         References [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}                                                                                                                                References [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}
  No. studies (n/N; total person‐months)   18 (3064/81 886; 497 624)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             21 (757/20 451; 458 114)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        5 (10/1124; 17 528)                                                                                                                                                                                                                                                                                                                                        5 (16/1146; 17 260)
  Estimated pooled rate (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Per month                                0.49% (0.19%; 0.95%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.11% (0.03%; 0.24%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            0.05% (0.01%; 0.14%)                                                                                                                                                                                                                                                                                                                                       0.08% (0.02%; 0.21%)
  Per year                                 5.88% (2.28%; 11.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.38% (0.42%; 2.88%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            0.58% (0.06%; 1.63%)                                                                                                                                                                                                                                                                                                                                       1.01% (0.19%; 2.47%)
  All deaths+MI                            References [7](#jah31924-bib-0007){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [41](#jah31924-bib-0041){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                           References [1](#jah31924-bib-0001){ref-type="ref"}, [2](#jah31924-bib-0002){ref-type="ref"}, [4](#jah31924-bib-0004){ref-type="ref"}, [7](#jah31924-bib-0007){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [11](#jah31924-bib-0011){ref-type="ref"}, [12](#jah31924-bib-0012){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [16](#jah31924-bib-0016){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [26](#jah31924-bib-0026){ref-type="ref"}, [29](#jah31924-bib-0029){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}                                                                                                                                                                                                                  References [14](#jah31924-bib-0014){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}                                                                                                                                                                          References [14](#jah31924-bib-0014){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}
  No. studies (n/N; total person‐months)   17 (7631/81 893; 494 260)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             17 (436/9376; 118 170)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          4 (22/944; 13 208)                                                                                                                                                                                                                                                                                                                                         4 (35/975; 13 156)
  Estimated pooled rate (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Per month                                1.07% (0.55%; 1.76%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  0.33% (0.13%; 0.62%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            0.18% (0.08%; 0.33%)                                                                                                                                                                                                                                                                                                                                       0.17% (0.02%; 0.49%)
  Per year                                 12.8% (6.59%; 21.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  3.96% (1.57%; 7.42%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            2.18% (0.95%; 3.91%)                                                                                                                                                                                                                                                                                                                                       2.03% (0.19%; 5.83%)

CAD indicates coronary artery disease; MACE, major adverse cardiovascular events; MI, myocardial infarction; n, Number of non‐obstructive CAD subjects; N, Number of obstructive CAD participants; NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease.
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Combining the few studies that separately considered mildly obstructed CAD patients (1--50% stenosis) and normal artery CAD patients (0% stenosis), the pooled yearly rates of death, myocardial infarction, and death plus myocardial infarction were 1.1%, 1.0%, and 2.0%, respectively, in mildly obstructive CAD patients, and 1.3%, 0.6%, and 2.2% in normal artery CAD patients (Table [3](#jah31924-tbl-0003){ref-type="table-wrap"}, Figures S49 through S54). No meta‐analysis of event rates was made for cardiac death and MACE because the number of studies with follow‐up longer than 6 months was too limited to allow meaningful analyses.

Clinical Outcomes in Nonobstructive Versus Obstructive CAD {#jah31924-sec-0014}
----------------------------------------------------------

As reported in Table [4](#jah31924-tbl-0004){ref-type="table-wrap"}, of the 22 studies (including a total of 96 179 participants) that directly compared at least 1 cardiovascular outcome in NObCAD versus ObCAD patients, 18 evaluated all‐cause mortality (n=93 178 participants); 8 cardiac death (n=9939); 14 myocardial infarction (n=77 966); 13 all‐cause mortality or myocardial infarction (n=77 858); and 7 evaluated MACE (n=12 289).

###### 

Meta‐Analyses Comparing the Risk of Clinical Outcomes of NObCAD Versus ObCAD Patients

  Outcomes^Refs.^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               No. Studies (No. Patients)   n/N                       Risk Ratio   95% CI         *P* Value   I^2^, %
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------- ------------ -------------- ----------- ---------
  MACE[18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      7 (12 289)                   104/967 vs 2039/11 322    0.53         0.44 to 0.64   \<0.001     0
  Stratified by follow‐up duration[a](#jah31924-note-0007){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  1 to 6 months[7](#jah31924-bib-0007){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            4 (11 943)                   41/584 vs 1574/11 359     0.51         0.38 to 0.69   \<0.001     0
  ≥12 months[18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    5 (6353)                     76/681 vs 945/5672        0.54         0.43 to 0.68   \<0.001     0
  All deaths[7](#jah31924-bib-0007){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [29](#jah31924-bib-0029){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [34](#jah31924-bib-0034){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}   18 (93 178)                  149/8120 vs 3180/85 058   0.53         0.40 to 0.70   \<0.001     57
  Stratified by follow‐up duration[a](#jah31924-note-0007){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  1 to 6 months[7](#jah31924-bib-0007){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [34](#jah31924-bib-0034){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}                                                                                                                                                                                                                                                                                                      11 (81 515)                  74/6681 vs 2160/74 834    0.45         0.28 to 0.72   \<0.001     66
  ≥12 months[17](#jah31924-bib-0017){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [29](#jah31924-bib-0029){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                        11 (23 784)                  87/2097 vs 1323/21 687    0.63         0.50 to 0.80   \<0.001     10
  Cardiac death[18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [30](#jah31924-bib-0030){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                   8 (9939)                     27/1093 vs 523/8846       0.44         0.19 to 0.98   0.05        69
  Stratified by follow‐up duration[a](#jah31924-note-0007){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  1 to 6 months[27](#jah31924-bib-0027){ref-type="ref"}, [30](#jah31924-bib-0030){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           4 (10 051)                   17/845 vs 438/9206        0.33         0.12 to 0.91   0.03        65
  ≥12 months[18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                7 (8337)                     16/743 vs 264/7594        0.66         0.38 to 1.15   0.14        12
  MI[7](#jah31924-bib-0007){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                         14 (77 966)                  97/6917 vs 2552/71 049    0.36         0.23 to 0.57   \<0.001     66
  Stratified by follow‐up duration[a](#jah31924-note-0007){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  1 to 6 months[7](#jah31924-bib-0007){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                    8 (76 368)                   81/6287 vs 2372/70 081    0.35         0.19 to 0.63   \<0.001     73
  ≥12 months[17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                            9 (10 047)                   21/1125 vs 446/8922       0.41         0.18 to 0.94   0.04        67
  All deaths+MI[7](#jah31924-bib-0007){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                        13 (77 858)                  178/6802 vs 6520/71 056   0.36         0.25 to 0.53   \<0.001     79
  Stratified by follow‐up duration[a](#jah31924-note-0007){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  1 to 6 months[7](#jah31924-bib-0007){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                    8 (76 368)                   143/6287 vs 6066/70 081   0.34         0.20 to 0.56   \<0.001     85
  ≥12 months[17](#jah31924-bib-0017){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                      8 (9939)                     51/1010 vs 913/8929       0.48         0.35 to 0.67   \<0.001     22

MACE indicates major adverse cardiovascular events; MI, myocardial infarction; n, Number of non‐obstructive CAD subjects; N, Number of obstructive CAD participants; NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease; Refs., references.

Some studies reported (diverse) data at different time‐points,[27](#jah31924-bib-0027){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"} and were included in both 1 to 6 and 12+ months meta‐analyses; thus the sum of the samples of the stratified meta‐analyses can be larger than the sample of the overall meta‐analysis.

John Wiley & Sons, Ltd

As compared with ObCAD patients, NObCAD subjects showed a significantly lower risk of all of the above cardiovascular outcomes (Table [4](#jah31924-tbl-0004){ref-type="table-wrap"}, Figures S55 through S59): the RR of both all‐cause death and MACE was 0.53; the RR of cardiac death was 0.44; and the RR of both myocardial infarction and death or myocardial infarction was 0.36 (all *P*\<0.05). The results were similar when analyses were stratified by the length of follow‐up, with the sole exception of cardiac death, which was not significant when only studies with follow‐up ≥12 months were included. No study reported a significant higher risk of any outcome for NObCAD versus ObCAD patients. The funnel plots displaying the RRs versus the logarithms of their standard errors appear skewed to the left for studies evaluating all‐cause mortality (Figure S60), but not for studies considering the other outcomes (Figures S61 through S64). The Egger weighted regression method to detect publication bias identified a borderline significant asymmetry for trials considering death (*P*=0.05).

Among NObCAD patients, the risks of all‐cause mortality, myocardial infarction, or all‐cause mortality plus myocardial infarction did not differ significantly between the subjects with mildly obstructed versus normal artery CAD (Table [5](#jah31924-tbl-0005){ref-type="table-wrap"}, Figures S65 through S67). However, few events were included in the above meta‐analyses, which lacked statistical power, and no meaningful quantitative analyses could be performed to evaluate cardiac death and MACE.

###### 

Meta‐Analyses Comparing the Risk of Clinical Outcomes of Mildly Obstructive Versus Normal Artery CAD Patients

  Outcomes^Refs.^                                                                                                                                                                                                                                                       No. Studies (No. Patients)   n/N                  Risk Ratio   95% CI         *P* Value   I^2^, %
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- -------------------- ------------ -------------- ----------- ---------
  All deaths[8](#jah31924-bib-0008){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}   6 (2861)                     25/1210 vs 41/1447   0.96         0.46 to 1.97   0.9         31
  MI[14](#jah31924-bib-0014){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}                                                                                                                                        3 (1715)                     7/836 vs 12/879      0.63         0.25 to 1.58   0.3         0
  All deaths+MI[14](#jah31924-bib-0014){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}                                                                                                                             3 (1715)                     18/836 vs 27/879     0.72         0.37 to 1.39   0.3         17

CAD indicates coronary artery disease; MI, myocardial infarction; n, Number of non‐obstructive CAD subjects; N, Number of obstructive CAD participants; Refs., references.

John Wiley & Sons, Ltd

Discussion {#jah31924-sec-0015}
==========

This meta‐analysis re‐analyzed all the data published regarding the clinical presentation and outcomes of NObCAD and ObCAD patients with ACS, attempting to address several questions and providing quantitative estimates that are difficult to obtain when studies are examined separately. The main findings are the following: (1) when compared to patients with obstructive CAD, the patients with a diagnosis of NObCAD showed a lower baseline cardiovascular risk as they are significantly less likely to be old, male, diabetic, hypertensive, or dyslipidemic; (2) non‐ST‐segment--ACS was the main pattern of presentation among patients with NObACS; (3) as logically follows from the above, NObCAD patients have one third to one half the likelihood of death or a main cardiovascular event than ObCAD subjects; (4) NObCAD subjects, however, are still at high risk for cardiovascular mortality and morbidity, showing yearly rates of death plus myocardial infarction or MACE as large as 4% and 9.2%, respectively. Interestingly, while in the short‐term follow‐up (1--6 months), the cardiac mortality rate was significantly lower in nonobstructive ACS patients, these differences did not persist through the 1‐year follow*‐*up, making the rates of cardiac death and myocardial infarction comparable between the 2 groups; (5) among NObCAD subjects, having zero stenosis rather than a mildly obstructive stenosis (1--49%) does not seem to be associated with a lower risk of death or cardiovascular outcomes, but these analyses are underpowered and require validation.

The better baseline CHD risk profile of NObCAD versus ObCAD subjects was already well known and documented in numerous studies, which listed several potential explanations related to the progression of the atherosclerotic plaque and hypothesized a stronger role of nonclassical risk factors (inflammation, insulin resistance, psychosocial factors, physical inactivity) in ACS etiology for NObCAD subjects.[6](#jah31924-bib-0006){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [49](#jah31924-bib-0049){ref-type="ref"}, [50](#jah31924-bib-0050){ref-type="ref"} This meta‐analysis adds quantitative estimates with tight confidence intervals on the distribution of the most common CHD risk factors in ObCAD and NObCAD groups, which can be used either for clinical practice or to support prognostic multivariate modeling.

In all but 6[27](#jah31924-bib-0027){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"} of the 60 direct comparisons, NObCAD patients showed a better prognosis than ObCAD subjects, with all meta‐analyses reporting significantly lower rates of events, from half to one third of those reported by ObCAD patients. Also, 5 of the 6 comparisons with divergent results were underpowered, including 5 or fewer events in the NObCAD group.[27](#jah31924-bib-0027){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"} In addition, a lower mortality rate for patients with myocardial infarction and nonobstructive coronary arteries was also documented in a recent systematic review.[6](#jah31924-bib-0006){ref-type="ref"} The most likely potential explanations for these findings include the younger age and the lower rate of diabetes mellitus (both of which are independent predictor of MACE) among NObCAD subjects. Also, given the drastically lower likelihood of baseline presentation with ST‐segment‐elevation--ACS of NObCAD patients, it has been suggested that their average amount of myocardial infarction might be smaller than that of ObCAD subjects.[42](#jah31924-bib-0042){ref-type="ref"}

It has been suggested that, among NObCAD patients, those with normal coronary arteries may carry a lower CHD risk than the subjects with mildly obstructed CAD, representing a different population of younger patients with a possible tendency for spontaneous thrombosis and other etiologies leading to CAD (eg, takotsubo cardiomyopathy, variant angina pectoris, microvascular dysfunction, and coronary vasospasm).[5](#jah31924-bib-0005){ref-type="ref"}, [6](#jah31924-bib-0006){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"} Indeed, a meta‐analysis of 18 studies including unselected or stable patients without significant epicardial coronary artery disease reported that coronary events were 6‐fold more frequent in patients with mild (0--20%) stenosis and 15‐fold more frequent in patients with moderate stenosis (20--40%), when compared with patients with smooth and normal arteriograms.[48](#jah31924-bib-0048){ref-type="ref"} From the present meta‐analysis, a different picture emerges for ACS. In the noncritical stenosis range, normal (0%) coronary arteries were associated with no better prognosis than a nonobstructive (1--49%) coronary stenosis. Such a discrepancy, however, may be artificial, because (1) our meta‐analyses restricted to NObCAD subjects included a very scarce number of events and were largely underpowered; (2) heterogeneous conditions were included under the umbrella term of NObACS, which may encompass disparate entities, such as epicardial artery coronary vasospasm, takotsubo acute cardiomyopathy, cocaine or other illicit drug abuse, spontaneous coronary dissection, or even acute myocarditis with ACS‐like presentation. In fact, a major concern in the clinical definition of nonobstructive ACS is that the majority of the included studies did not carry out special diagnostic investigations to rule out the potential role of microcirculation as a cause of myocardial acute injury (as shown in Table S4), nor were diagnostic tests carried out to assess the effective vessel atherosclerotic burden that is often undetectable at angiography due to negative atherosclerotic remodeling.[49](#jah31924-bib-0049){ref-type="ref"}

Although the prognostic profile of NObCAD patients was more favorable than ObCAD subjects, the former showed absolute yearly rates of events as high as 9.2% (MACE) and 4.0% (all deaths plus myocardial infarction), in clear contrast with the common assumption of a good prognosis for NObCADs.[40](#jah31924-bib-0040){ref-type="ref"} Given that the underlying mechanisms that lead to clinical presentation of ACS in NObCAD subjects are not well understood,[5](#jah31924-bib-0005){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"} and that the appropriate therapeutic approach for such patients is also unknown,[31](#jah31924-bib-0031){ref-type="ref"} it has been suggested that their unfavorable outcome might be explained, at least in part, by the lower rate of the prescription of β‐blockers, angiotensin‐converting enzyme inhibitors, statins, and antiplatelet drugs.[10](#jah31924-bib-0010){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"} In our meta‐analysis, all of the above drugs were less frequently prescribed to NObCAD patients. Unfortunately, none of the included studies reported data on dual antiplatelet therapy, which is one of the most important disease‐modifying medications, when left ventricular function is preserved. However, while the vast majority of patients in both groups received aspirin (81.7% and 86.8% in NObCAD and ObCAD groups, respectively), P2Y12 inhibitors were administered only to 29.2% and NObCAD patients (and 63.7% ObCAD subjects), and it could thus be hypothesized that only a minority of patients with NObCAD were under dual antiplatelet therapy. This might be due to the fact that the decision to treat patients was driven by angiographic results rather than by clinical presentation, supporting the hypothesis that these patients are often undertreated, probably in the belief that NObCAD represents a benign condition.[40](#jah31924-bib-0040){ref-type="ref"} Overall, our findings reinforce the calls for a specific management or an expansion of formal guidelines to include specific recommendations for secondary prevention measures in NObCAD patients.[5](#jah31924-bib-0005){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}

Limitations {#jah31924-sec-0016}
-----------

Several limitations should be considered in the interpretation of our data. First, the heterogeneity across studies was substantial in both the baseline characteristics and the length of follow‐up. While quantifying the differences in baseline characteristics was one of the aims of the analysis, we computed yearly and monthly rates rather than the overall rates of event to reduce the potential bias deriving from varying follow‐ups. In any case, it cannot be excluded that the higher event rate that typically occurs in the first 6 months of follow‐up might have led to an overestimate of the event rates in those comparisons where the number of short‐term follow‐up studies was larger. Second, meta‐regression might have been used to explore both the causes of heterogeneity and the independent contribution of each of the CAD risk factors in determining the excess risk in ObCAD versus NObCAD subjects. However, any meta‐regression model that we fit was at serious risk of bias due to the relatively scarce number of individual studies in each meta‐analysis and, most importantly, due to the serious imbalance in each study sample size between NObCAD and ObCAD subjects (with 1 NObCAD each 6--20 ObCAD subjects for many studies). This implies that the overall value of a determined risk factor (eg, age) of an unbalanced study (eg, Dokainish et al[7](#jah31924-bib-0007){ref-type="ref"}) is very similar to the mean age value of the ObCAD group, and studies with balanced groups seem to have a lower mean age than those with unbalanced groups, regardless of their relative risk of event. Even exploring other alternative options (eg, age differential between each study group), the bias caused by the scarce number of balanced‐group studies determined a serious lack of reliability for any meta‐regression, the results of which were thus not shown. Third, as for all meta‐analyses based upon published studies, although we made an extensive systematic search, we cannot exclude that additional data exist that were not considered. Fourth, as previously noted, some of the meta‐analyses were populated by a low number of events and certainly require confirmation from additional data.

Conclusions {#jah31924-sec-0017}
===========

This meta‐analysis confirms that ACS patients with and without obstructive CAD are significantly different. NObCAD patients have a significantly lower cardiovascular risk at baseline and a subsequent lower rate of death or a main cardiovascular event. However, these subjects are still at high risk for cardiovascular mortality and morbidity, suggesting potential undertreatment and calling for a specific management. Our findings, other than demonstrating a significant medical treatment gap, highlight an important opportunity for improving the quality of care and, in turn, the outcomes of patients being diagnosed with NObACS.[50](#jah31924-bib-0050){ref-type="ref"} In the context of NObCAD, no differences in prognosis were noted between zero stenosis versus mildly obstructive stenosis (1--49%), but such analyses require validation.

Author Contributions {#jah31924-sec-0018}
====================

All authors participated in the design, analysis, and interpretation of the study. Manzoli, Flacco, and Pizzi were involved in all phases of the study. Xhyheri, Costa, and Pizzi made the bibliographic search. Manzoli and Flacco led the statistical analysis, Gualano and Xhyheri performed the data extraction. Gualano carried out the methodological quality assessment. Manzoli, Flacco, and Pizzi wrote the manuscript, which was revised by Costa and Fragassi. Manzoli had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosures {#jah31924-sec-0019}
===========

None.

Supporting information
======================

###### 

**Appendix S1.** Supplemental figures, tables, and references.

###### 

Click here for additional data file.

References [7](#jah31924-bib-0007){ref-type="ref"}, [8](#jah31924-bib-0008){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [10](#jah31924-bib-0010){ref-type="ref"}, [12](#jah31924-bib-0012){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [17](#jah31924-bib-0017){ref-type="ref"}, [18](#jah31924-bib-0018){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [23](#jah31924-bib-0023){ref-type="ref"}, [25](#jah31924-bib-0025){ref-type="ref"}, [26](#jah31924-bib-0026){ref-type="ref"}, [27](#jah31924-bib-0027){ref-type="ref"}, [28](#jah31924-bib-0028){ref-type="ref"}, [29](#jah31924-bib-0029){ref-type="ref"}, [30](#jah31924-bib-0030){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [34](#jah31924-bib-0034){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [37](#jah31924-bib-0037){ref-type="ref"}, [38](#jah31924-bib-0038){ref-type="ref"}, [39](#jah31924-bib-0039){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [41](#jah31924-bib-0041){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}, [43](#jah31924-bib-0043){ref-type="ref"}, [44](#jah31924-bib-0044){ref-type="ref"}.

References [8](#jah31924-bib-0008){ref-type="ref"}, [9](#jah31924-bib-0009){ref-type="ref"}, [12](#jah31924-bib-0012){ref-type="ref"}, [13](#jah31924-bib-0013){ref-type="ref"}, [14](#jah31924-bib-0014){ref-type="ref"}, [15](#jah31924-bib-0015){ref-type="ref"}, [23](#jah31924-bib-0023){ref-type="ref"}, [25](#jah31924-bib-0025){ref-type="ref"}, [26](#jah31924-bib-0026){ref-type="ref"}, [32](#jah31924-bib-0032){ref-type="ref"}, [41](#jah31924-bib-0041){ref-type="ref"}.

References[15](#jah31924-bib-0015){ref-type="ref"}, [19](#jah31924-bib-0019){ref-type="ref"}, [20](#jah31924-bib-0020){ref-type="ref"}, [22](#jah31924-bib-0022){ref-type="ref"}, [30](#jah31924-bib-0030){ref-type="ref"}, [31](#jah31924-bib-0031){ref-type="ref"}, [35](#jah31924-bib-0035){ref-type="ref"}, [36](#jah31924-bib-0036){ref-type="ref"}, [40](#jah31924-bib-0040){ref-type="ref"}, [42](#jah31924-bib-0042){ref-type="ref"}.
